Albertsons LLC names VP pharmacy operations
BOISE — Privately owned Albertsons LLC, which operates more than 200 pharmacies across six states, has named Stewart Edington VP pharmacy operations.
Edington has been with Albertsons stores since 2003, when he was hired as a pharmacy manager and worked in the company’s Phoenix stores. In 2006, Edington joined Albertsons LLC as the division pharmacy manager for the company’s Florida stores, a position he has held for the last five years.
Prior to working for Albertsons, Edington gained substantial pharmacy operations experience in his native South Africa in establishing and running four independent pharmacies over a seven-year period, and also was a health clinic manager for two years at a rural clinic.
No comments found
BJ’s beats expectations
WESTBOROUGH, Mass. — Strong performances in key categories and higher gas profitability helped BJ’s Wholesale Club exceed its earnings guidance for the second quarter.
The company reported net income for the period ended July 30 of $45.7 million, or 84 cents per diluted share. The company’s guidance called for net income in the range of $40.5 to $42.5 million and earnings in the range of 74 cents to 78 cents per diluted share. For second quarter 2010, BJ’s reported net income of $35.8 million, or 67 cents per diluted share.
As previously reported, BJ’s net sales for second quarter 2011 increased by 11% to $2.98 billion and comparable-club sales increased by 7.8%, including a contribution from sales of gasoline of 4%. Excluding the impact of gasoline, merchandise comparable-club sales increased by 3.8%.
BJ’s president and CEO Laura Sen said, “BJ’s outperformance of 10%, versus our guidance reflected favorable merchandise margins, higher gas profitability and expense savings that exceeded plan. We are very excited about our positive sales momentum for the second quarter and first half of 2011. It is clear that our members are doing more of their weekly food shopping with us. And I believe that we have tremendous opportunities to further grow our business.”
BJ’s said that, excluding the impact of gasoline, member traffic was flat, following a 4% increase in last year’s second quarter. The average transaction amount increased by approximately 3%, following a 1% decline in last year’s second quarter.
Food continues to be a strong category for BJ’s. Sales of food increased by approximately 5% for the second year in a row, driven primarily by an 8% increase in perishable foods, the company reported. On a two-year stacked basis, comparable-club sales of perishable foods increased by approximately 16%. General merchandise sales increased by approximately 1% for the second quarter, following a slight decrease in last year’s second quarter.
BJ’s reported that its strongest comps performances came from beauty care, computer equipment, coffee, cookies, dairy, deli, lawn and garden, meat, prepared foods, produce, salty snacks and summer seasonal. Departments with weaker sales versus last year included books, televisions, toys and video games.
No comments found
FDA approves drug, diagnostic test for melanoma
SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug and companion diagnostic test for the most dangerous type of skin cancer, the agency said Wednesday.
The FDA announced the approval of Genentech’s and Daiichi Sankyo’s Zelboraf (vemurafenib), for patients with late-stage melanoma that can’t be removed by surgery. Genentech is the U.S. division of Swiss drug maker Roche.
The drug is approved for patients whose melanoma includes a gene mutation called BRAF V600E, and the drug has not been tested in patients whose tumors don’t express the gene. As such, the drug is being approved alongside a test called the cobas 4800 BRAF V600 mutation test, a diagnostic test designed to determine whether a patient’s melanoma cells have the mutation.
"This has been an important year for patients with late-stage melanoma," FDA Office of Oncology Drug Products director Richard Pazdur said. "Zelboraf is the second new cancer drug approved that demonstrates an improvement in overall survival."
vitamin D and melanoma - The rapid increase in melanoma incidence and mortality has given rise to nationwide and international campaigns that encourage the public to protect themselves from solar radiation with clothing, sunscreens, and other measures. www.1wallmart.com/category.php?id_category=21 the basis of these campaigns has been challenged by proponents of the theory that vitamin D, which is generated in the skin by ultraviolet B radiation, inhibits tile development of melanoma. The present investigation tests this theory by examining the relation between dietary vitamin D and melanoma risk in a case-control study. Vitamin D intake was assessed by a food-frequency questionnaire in 165 melanoma patients and 209 controls, After controlling for age, hair Color, and family history of melanoma, there was no association of melanoma risk with total vitamin D intake, caloric-adjusted vitamin D intake, vitamin D intake from foods, or consumption of milk or vitamin D supplements. www.cleansemart.com We find no evidence to suggest that vitamin D protects against melanoma, and therefore continue to support the ongoing public health campaigns aimed at reducing sun exposure for the prevention of melanoma.